- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Roger Longman Offers Strategies to Analyze the Value of Emerging Drugs With Limited Real-World Data
Using value assessment models and data that predict real-world performance can assist in valuing drugs with limited or no real-world data, said Roger Longman, MA, chief executive officer of Real Endpoints.
Using value assessment models and data that predict real-world performance can assist in valuing drugs with limited or no real-world data, said Roger Longman, MA, chief executive officer of Real Endpoints.
Transcript
How can the US healthcare system do a better job of adequately analyzing the value of drugs, particularly new drugs that have less, or no, real-world data available?
Well, I think there are probably several ways they can do it. One is they can do a better job of more objectively measuring value and there a number of value assessment systems which have been developed including—ICER is the most obvious. The other point is that there are now contracting opportunities where you can actually go at risk for the value of a drug based on a performance. One of the things that allows you to do is to gather data on that drug through its use and ultimately use that data to either demonstrate that the clinical trials in fact predict real-world performance, or in fact, could generate other kinds of utilities for that drug that can be used then in negotiations with other payers. It’s real-world data so it’s more credible. So, these kinds of risk sharing agreements are in fact a way of creating data for drugs which don’t have the kind of data that would be required to truly judge their performance apriori.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
A Look at the Legal and Legislative Landscape Impacting Drug Costs for Patients
October 23rd 2024Kimberly Westrich, MA, of National Pharmaceutical Council, and Adam Colborn, JD, of AMCP, run through the current status of lawsuits and lawmaking at the federal and state levels related to pharmacy benefit managers and cost-shifting programs.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
